| 384 |
Study of Protease Inhibitor and/or Non-Nucleoside Reverse Transcriptase Inhibitor with Dual Nucleosides in Initial Therapy of HIV Infection |
10/98 to 11/99 |
| A5014 |
A Randomized, Open-Label, Pilot Treatment Trial Evaluating Cellular Dynamics and Immune Restoration in Treatment-Naive HIV-Infected Subjects Receiving Either the Protease Inhibitor LPV/r or the Nucleoside Reverse Transcriptase Inhibitors d4T/3TC/Abcavir with the Non-Nucleoside Reverse Transcriptase Inhibitor Nevirapine |
3/00 to 3/01 |
| A5095 |
Phase III, Randomized, Double-Blind Comparison of Three Protease Inhibitor-Sparing Regimens for the Initial Treatment of HIV Infection |
3/01 to 11/02 |
| A5142 |
A Phase III, Randomized, Open-Label Comparison of Lopinavir/Ritonavir plus Efavirenz vs. Lopinavir/Ritonavir plus 2 NRTIs vs. Efavirenz plus 2 NRTIs for the Initial Therapy for HIV-1 Infection |
1/03 to 4/04 |
| 347 |
A Randomized, Double-Blind Phase 2 Study of VX-478 Monotherapy vs VX-478 plus ZDV plus 3TC in HIV Infected Individuals |
3/97 to 6/97 |
| 388 |
A Phase III, Randomized, Controlled Trial of Efavirenz (EFV) or Nelfinavir (NFV) in Combination with Fixed-Dose Combination Lamivudine/Zidovudine (3TC/ZDV) and Indinavir (IDV) in HIV-Infected Subjects with <=200 CD4 Cells/MM3 or >= 80,000 HIV RNA Copies/m |
6/98 to 1/99 |
| 364 |
Comparison of the Virologic Efficacy of Nelfinavir and/or DMP-266 in Combination with One or Two Nucleoside Analogs in Nucleoside Experienced Subjects: A Rollover Study of ACTG 302/303 |
7/97 to 9/97 |
| 372 |
A Phase II Study of the Prolongation of Virologic Success & Options for Virologic Failure in HIV-Infected Subjects Receiving IDV in Combination with Nucleoside Analogs: A Rollover Study to ACTG 320 |
10/97 to 1/98 |
| 373 |
An Open Label Phase II Study of Amprenavir (141W94/VX-478) Plus 3TC Plus ZDV or Indinavir Plus 3TC Plus d4T Plus NVP in Patients Previously Treated with Amprenavir (141W94/VX-478) (ACTG 347 Rollover Study) |
11/97 to 4/98 |
| 398 |
A Phase II, Randomized Trial of APV as Part of Dual PI Regimens (Placebo Controlled) in Combination with ABC, EFV & ADV vs. APV Alone in HIV Infected Subjects with Prior Exposure to Approved PIs and Loss of Virologic Suppression as Reflected By A Plasma HIV-1 RNA of >= 1000 copies/ml |
10/98 to 4/99 |
| 400 |
A Randomized, Open Label, Comparative Trial of Salvage Antiretroviral Therapies for HIV-Infected Individuals with Virological Evidence of Nelfinavir Treatment Failure |
12/98 to 11/99 |
| A5025 |
A Phase II, Randomized Study of the Safety and Efficacy of Hydroxyurea in Subjects on Potent Antiretroviral Therapy with Less than 200 copies/ml of HIV RNA in the Plasma |
11/98 to 5/99 |
| A5064 |
A Pilot Study of Early Treatment Intensification of Antiretroviral Therapy |
3/00 to 5/01 |
| A5076 |
HIV-1 Resistance Testing During Antiretroviral Failure: Comparison Of Sequencing versus Phenotyping |
1/01 to 12/01 |
| A5110 |
Restrictively Randomized, Open-Label, Controlled, Pilot Study of the Effect of a Thymidine Analogue Substitution or Change to a Nucleoside-Sparing Regimen on Peripheral Fat Wasting |
5/02 to 4/04 |
| A5115 |
A Phase II Randomized, Controlled, Pilot Study of Antiretroviral Switch at Lower versus Higher HIV-1 RNA Levels in Subjects Experiencing Virologic Relapse on a Current HAART Regimen |
9/02 to 4/04 |
| A5126 |
A Phase II Study of the Predictive Value of Pharmacokinetic-Adjusted Phenotypic Susceptibility (C12h/IC50) on Antiretroviral Response to Ritonavir-Enhanced Protease Inhibitors in Subjects with Failure of Previous Protease Inhibitor-Based Regimensc |
6/02 to 3/03 |
| A5135 |
A Phase II, Randomized, Open-Label Study Comparing Fixed-Dose versus Concentration-Adjusted Lopinavir/Ritonavir Therapy in HIV-infected Subjects on Salvage Therapy |
2/03 to 6/03 |
| A5143 |
A Randomized, Comparative Study of LPV/RTV vs. GW433908 + RTV vs. LPV/RTV + GW433908 (in Combination with Tenofovir Disoproxil Fumarate and One or Two Nucleoside Reverse Transcriptase inhibitors) in HIV-1-Infected Subjects with Virologic Treatment Failure |
10/02 to 7/03 |
| A5146 |
A Phase II Randomized Controlled Trial Evaluating the Impact of Therapeutic Drug Monitoring (TDM) on Virologic Response to a Salvage Regimen in Subjects with a Normalized Inhibitory Quotient (NIQ) <= 1 to One or More Protease Inhibitors |
12/02 to 5/06 |
| A5211 |
Phase II, Randomized, Double-Blind Study of the Safety and Efficacy of SCH 417690 (an Orally Administered HIV-1 Entry Inhibitor) in HIV-Infected Treatment -Experienced Subjects |
7/04 to 9/05 |
